This post has expired! It was posted more than 90 days ago.
<- Back

133040 - PPI: Reviewing treatment for gastro-oesophageal reflux disease - National Case Study

  • : Online


This online interactive case study supports best practice use of proton pump inhibitors (PPIs) for managing GORD, specifically addressing the recommended use of PPIs, providing guidance on starting, stepping down and stopping treatment, as well as long-term risks.

Relevance to General Practice

Gastro-oesophageal reflux is common, with 15-20% of Australians experiencing heartburn at least once a week. Gastro-oesophageal reflux disease (GORD) occurs when patients experience symptoms of reflux which are frequent (two or more episodes per week) or severe enough to significantly impair quality of life, and is managed primarily with lifestyle changes and medicines. 

Current guidelines for GORD recommend starting treatment on a short-term standard-dose PPI (4-8 weeks), followed by regular review to step down to the lowest effective dose, or stop the medicine completely. However, evidence suggests most PPIs are being used long term, often unnecessarily and without appropriate indication. 

While PPIs are generally considered safe, there is some emerging evidence of rare but serious adverse effects that also need to be considered. 

This online interactive case study will address the management of GORD, specifically focusing on the appropriate use of PPIs. 

Learning outcomes
  • Develop a plan when starting treatment for GORD, including lifestyle changes and PPI therapy, with clarity on stepping down or stopping, and review times
  • Apply guideline recommendations for proton pump inhibitor (PPI) use in gastro-oesophageal reflux disease (GORD)
  • List rare but serious adverse effects associated with PPI therapy
  • Explain the advantages and barriers to stepping down and stopping PPI therapy in patients with adequately controlled GORD symptoms
  • Discuss and manage expectations when stepping down or stopping PPI, and provide strategies to manage potential rebound acid hypersecretion
  • Delivery
    133040 - PPI: Reviewing treatment for gastro-oesophageal reflux disease - National Case Study
    1 hour
    Start Date
    End Date
    CPD Points
    1 hour
    Contact Phone
    Log in into view this field.